FDA strikes twice for Cerus

Three days after FDA approved the Intercept Blood System for plasma, Cerus Corp. (NASDAQ:CERS) announced

Read the full 158 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE